Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NovoCure LtdNVCR · Entity 4494 | Chief Human Resources Officer | June 30, 2023 | July 06, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NovoCure Ltd
Report date June 30, 2023 · Filed July 06, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 66,447 |
Reported balance
After 2023-06-30 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-06-30 · Grant · Acquired 357 · Balance 66,447 F1: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January1, 2023 through June 30, 2023. This transaction is also exempt under Rule 16b-3(c). F2: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on June 30, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January1, 2023 through June 30, 2023. This transaction is also exempt under Rule 16b-3(c).
F2: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on June 30, 2023.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 30, 2023 Filed Jul 6, 2023 16:14 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 357 | $35.28 | $12,594.96 |
DisclosureSEC source: 0001562180-23-005759 · primarydocument.xml · nonDerivative · entry 1 Burke William Patrick · CIK 0001880493 · Chief Human Resources Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,447 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January1, 2023 through June 30, 2023. This transaction is also exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on June 30, 2023. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 16:50 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 593 | $76.16 | $45,162.52 |
DisclosureSEC source: 0001562180-23-002577 · primarydocument.xml · nonDerivative · entry 1 Burke William Patrick · CIK 0001880493 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,090 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 02, 2023 Filed Mar 6, 2023 16:42 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 281 | $75.28 | $21,153.09 |
DisclosureSEC source: 0001562180-23-002493 · primarydocument.xml · nonDerivative · entry 1 Burke William Patrick · CIK 0001880493 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,683 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 01, 2023 Filed Mar 2, 2023 16:51 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 755 | $76.36 | $57,653.61 |
DisclosureSEC source: 0001645113-23-000026 · wf-form4_167779384761589.xml · nonDerivative · entry 2 Burke William Patrick · CIK 0001880493 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,964 F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 16:51 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOptions to Buy Ordinary Shares · Derivative | 20,168 | $76.97 Strike: $76.97 | $1,552,330.96 |
DisclosureSEC source: 0001645113-23-000026 · wf-form4_167779384761589.xml · derivative · entry 3 Burke William Patrick · CIK 0001880493 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,168 Underlying: Ordinary Shares · 20,168 shares Expires 2033-02-27 F3 · derivative.exercise_date: Options to buy 20,168 ordinary shares will vest and become exercisable in equal installments on each of February 28, 2024, 2025, 2026 and 2027, subject to the reporting person's continued employment through such dates. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 16:51 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 12,125 | $0.00 | $0.00 |
DisclosureSEC source: 0001645113-23-000026 · wf-form4_167779384761589.xml · nonDerivative · entry 1 Burke William Patrick · CIK 0001880493 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,719 F1 · shares: Represents restricted share units that are scheduled to vest in equal installments on February 28, 2024, 2025 and 2026, subject to the reporting person's continued employment through such dates. Read SEC document |
| January 06, 2023 Filed Jan 10, 2023 16:13 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 108 | $62.31 | $6,728.94 |
DisclosureSEC source: 0001645113-23-000011 · wf-form4_167338521511152.xml · nonDerivative · entry 1 Burke William Patrick · CIK 0001880493 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,594 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of July 1, 2022 through December 30, 2022. This transaction is also exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on July 1, 2022. Read SEC document |
| September 02, 2022 Filed Sep 6, 2022 17:16 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 718 | $79.04 | $56,748.57 |
DisclosureSEC source: 0001645113-22-000078 · wf-form4_166249898623741.xml · nonDerivative · entry 1 Burke William Patrick · CIK 0001880493 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,486 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted stock units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| July 05, 2022 Filed Jul 7, 2022 17:44 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 213 | $59.08 | $12,582.98 |
DisclosureSEC source: 0001645113-22-000058 · wf-form4_165723028456783.xml · nonDerivative · entry 1 Burke William Patrick · CIK 0001880493 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,204 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2022 through June 30, 2022. This transaction is also exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on June 30, 2022. Read SEC document |
| March 08, 2022 Filed Mar 9, 2022 16:53 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 1,037 | $70.10 | $72,693.70 |
DisclosureSEC source: 0001645113-22-000028 · wf-form4_164686280769622.xml · nonDerivative · entry 1 Burke William Patrick · CIK 0001880493 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,991 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 04, 2022 Filed Mar 7, 2022 18:17 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 1,026 | $70.41 | $72,237.58 |
DisclosureSEC source: 0001645113-22-000016 · wf-form4_164669502376914.xml · nonDerivative · entry 3 Burke William Patrick · CIK 0001880493 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,028 F2 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 03, 2022 Filed Mar 7, 2022 18:17 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOptions to Buy Ordinary Shares · Derivative | 4,361 | $80.59 Strike: $80.59 | $351,452.99 |
DisclosureSEC source: 0001645113-22-000016 · wf-form4_164669502376914.xml · derivative · entry 5 Burke William Patrick · CIK 0001880493 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,361 Underlying: Ordinary Shares · 4,361 shares Expires 2032-02-29 F4 · shares: Options to buy 4,361 ordinary shares will vest and become exercisable in equal installments on each of March 1, 2023 and 2024, subject to the reporting person's continued employment through such dates. Read SEC document |
| March 03, 2022 Filed Mar 7, 2022 18:17 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOptions to Buy Ordinary Shares · Derivative | 13,038 | $80.59 Strike: $80.59 | $1,050,732.42 |
DisclosureSEC source: 0001645113-22-000016 · wf-form4_164669502376914.xml · derivative · entry 4 Burke William Patrick · CIK 0001880493 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,038 Underlying: Ordinary Shares · 13,038 shares Expires 2032-02-29 F3 · shares: Options to buy 13,038 ordinary shares will vest and become exercisable in equal installments on each of March 1, 2023, 2024, 2025 and 2026, subject to the reporting person's continued employment through such dates. Read SEC document |
| March 03, 2022 Filed Mar 7, 2022 18:17 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 341 | $74.50 | $25,403.82 |
DisclosureSEC source: 0001645113-22-000016 · wf-form4_164669502376914.xml · nonDerivative · entry 2 Burke William Patrick · CIK 0001880493 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,054 F2 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 03, 2022 Filed Mar 7, 2022 18:17 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 7,445 | $0.00 | $0.00 |
DisclosureSEC source: 0001645113-22-000016 · wf-form4_164669502376914.xml · nonDerivative · entry 1 Burke William Patrick · CIK 0001880493 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,395 F1 · kind: Represents restricted share units that are scheduled to vest in equal installments on March 1, 2023, 2024 and 2025, subject to the reporting person's continued employment through such dates. Read SEC document |
| January 06, 2022 Filed Jan 12, 2022 17:39 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 80 | $63.82 | $5,105.44 |
DisclosureSEC source: 0001645113-22-000007 · wf-form4_164202718179026.xml · nonDerivative · entry 1 Burke William Patrick · CIK 0001880493 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,950 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of July 1, 2021 through December 31, 2021. This transaction is also exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on December 31, 2021. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 16:52 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 1,402 | $0.00 Strike: $21.60 | $0.00 |
DisclosureSEC source: 0001645113-22-000001 · wf-form4_164141953630928.xml · derivative · entry 9 Burke William Patrick · CIK 0001880493 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,098 Underlying: Ordinary Shares · 1,402 shares Expires 2027-10-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 16:52 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 9,750 | $0.00 Strike: $7.15 | $0.00 |
DisclosureSEC source: 0001645113-22-000001 · wf-form4_164141953630928.xml · derivative · entry 8 Burke William Patrick · CIK 0001880493 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 9,750 shares Expires 2027-02-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 16:52 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 17,452 | $0.00 Strike: $11.46 | $0.00 |
DisclosureSEC source: 0001645113-22-000001 · wf-form4_164141953630928.xml · derivative · entry 7 Burke William Patrick · CIK 0001880493 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 17,452 shares Expires 2026-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 16:52 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 399 | $76.03 | $30,335.97 |
DisclosureSEC source: 0001645113-22-000001 · wf-form4_164141953630928.xml · nonDerivative · entry 6 Burke William Patrick · CIK 0001880493 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,870 F1 · shares: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Burke. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 16:52 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 1,402 | $21.60 | $30,283.20 |
DisclosureSEC source: 0001645113-22-000001 · wf-form4_164141953630928.xml · nonDerivative · entry 5 Burke William Patrick · CIK 0001880493 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,269 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Burke. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 16:52 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 919 | $76.09 | $69,923.95 |
DisclosureSEC source: 0001645113-22-000001 · wf-form4_164141953630928.xml · nonDerivative · entry 4 Burke William Patrick · CIK 0001880493 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,867 F2 · price: On January 3, 2022, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Burke, Mr. Burke sold 919 shares in multiple trades at prices ranging from $76.00 to $76.09. The price reported above reflects the weighted average sale price. Mr. Burke hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 16:52 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 9,750 | $7.15 | $69,712.50 |
DisclosureSEC source: 0001645113-22-000001 · wf-form4_164141953630928.xml · nonDerivative · entry 3 Burke William Patrick · CIK 0001880493 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,786 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Burke. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 16:52 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 2,633 | $75.96 | $200,002.68 |
DisclosureSEC source: 0001645113-22-000001 · wf-form4_164141953630928.xml · nonDerivative · entry 2 Burke William Patrick · CIK 0001880493 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,036 F1 · shares: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Burke. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 16:52 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 17,452 | $11.46 | $199,999.92 |
DisclosureSEC source: 0001645113-22-000001 · wf-form4_164141953630928.xml · nonDerivative · entry 1 Burke William Patrick · CIK 0001880493 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,669 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Burke. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.